Articles published by Genentech
![](https://mms.businesswire.com/media/20220815005009/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
August 11, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20220801005675/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
August 02, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20220727005958/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220714005018/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220710005020/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220629005007/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220616005106/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220609005656/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220530005033/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220526005089/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220523005210/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220510006484/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220428006028/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220403005050/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220403005023/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
April 04, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20220329005953/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
March 30, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20220324005883/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting
March 25, 2022
From Genentech
Via Business Wire
Tickers
OTC
![](https://mms.businesswire.com/media/20220316005106/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220210005045/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220128005009/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss
January 28, 2022
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20220124005816/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20220120005087/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20211214005594/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20211212005145/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20211211005049/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
December 11, 2021
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20211210005111/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20211123005629/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
![](https://mms.businesswire.com/media/20211022005479/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
October 22, 2021
From Genentech
Via Business Wire
Tickers
RHHBY
![](https://mms.businesswire.com/media/20211015005506/en/1138268/5/GENE_LOCKUP_Primary_FullColor_RGB_square.jpg)
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
October 15, 2021
From Genentech
Via Business Wire
Tickers
RHHBY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.